Pfizer says it's a "golden age" for drug discovery

Despite losing patent protection for the world's bestselling drug next year, Pfizer (NYSE: PFE) R&D chief Martin Mackay says the company will be sitting pretty for years to come, thanks to its pipeline and the acquisition of Wyeth last year. "We're in the golden age of drug discovery," Mackay says. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.